Gonadorelin — Research Dossier
Evidence grading
Identity
Synthetic GnRH
Identical to endogenous hypothalamic GnRH decapeptide
Site of action
Pituitary
Downstream of kisspeptin; direct GnRH receptor agonist
Pulsatile effect
Stimulates LH/FSH
Mimics physiological GnRH rhythm; basis for fertility use
Continuous effect
Downregulation
Desensitises GnRH receptor; basis for long-acting agonist therapy
Gonadorelin is synthetic GnRH — identical to the endogenous hypothalamic hormone — with a genuine pharmaceutical approval history as a diagnostic and fertility agent, and the defining mechanistic feature that pulsatile and continuous administration produce opposite effects on the HPG axis.
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the decapeptide identical to the endogenous hypothalamic hormone that drives the reproductive axis. It acts one level downstream of kisspeptin in the HPG cascade: where kisspeptin stimulates the GnRH neurons to fire, gonadorelin is GnRH itself, acting directly on GnRH receptors in the anterior pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH). This positional distinction matters and the two are not interchangeable.
Gonadorelin has a genuine pharmaceutical history as a diagnostic and fertility agent, used clinically to assess pituitary gonadotroph responsiveness (GnRH stimulation testing) and to treat primary hypothalamic amenorrhoea via pulsatile pump delivery. Several branded products have been discontinued and the molecule has been largely superseded in some indications by GnRH analogues with more convenient pharmacokinetics. Current brand availability and approval status vary by jurisdiction and have changed over time.
“Head-to-head intravenous comparison showed gonadorelin (GnRH), kisspeptin-10, and kisspeptin-54 all stimulate LH and FSH in healthy men, placing kisspeptin upstream of GnRH in the HPG cascade and confirming gonadorelin acts at the pituitary level.”
— Dhillo WS et al., comparison of IV kisspeptin-10, kisspeptin-54 and GnRH (PMC4507333)
Mechanism: pulsatile versus continuous
Gonadorelin binds GnRH receptors on anterior-pituitary gonadotrophs to stimulate LH and FSH release, which drive gonadal steroidogenesis. The defining pharmacological feature is dose-pattern dependence:
- Pulsatile administration: mimics physiological GnRH and stimulates LH/FSH secretion. This was the basis for its fertility and diagnostic uses, delivered via pulsatile infusion pump to replicate the natural GnRH pulse frequency.
- Continuous administration: desensitises and downregulates the GnRH receptor, suppressing the axis. This is the principle underlying long-acting GnRH-agonist therapy (e.g., leuprorelin) in oncology, endometriosis, and related indications.
Gonadorelin has a very short plasma half-life (minutes), which is why pulsatile delivery via infusion pump was used clinically rather than simple injection.
Clinical evidence base and pharmaceutical history
Gonadorelin's actions on LH and FSH are among the best-established pharmacological relationships in reproductive endocrinology. It has been used as a reference comparator in human studies, including head-to-head comparison with kisspeptin-10 and kisspeptin-54 on gonadotrophin secretion in healthy men (PMC4507333).
It was approved as a diagnostic agent for assessing pituitary gonadotroph responsiveness (GnRH stimulation testing) and as a treatment for primary hypothalamic amenorrhoea under brands including Factrel and HRF. Several branded products are discontinued; current availability and regulatory status vary by jurisdiction and should be verified before relying on any specific approval claim.
Regulatory status
Gonadorelin has a genuine regulatory history as an approved diagnostic and fertility agent in multiple jurisdictions, distinguishing it from never-approved research peptides. Several branded forms are discontinued and current availability is limited. It is not a controlled substance. As an agent affecting the reproductive and endocrine axis it has anti-doping relevance — verify current WADA listing. Material supplied for laboratory work is research-use-only in the UK.
Evidence grade: Approved (with caveats). The mechanism and clinical pharmacology are thoroughly established and the molecule is identical to native GnRH. The "approved" grade reflects its pharmaceutical history; current brand availability is limited and research-community uses fall outside its original approved indications.
See also
References
- 1
Schally AV, et al. Isolation and structure of gonadotropin-releasing hormone (GnRH) — foundational characterisation of the hypothalamic decapeptide Science / J Biol Chem 1971.
- 2
Dhillo WS, et al. Comparison of IV kisspeptin-10, kisspeptin-54 and GnRH (gonadorelin) on gonadotrophin secretion in healthy men Clin Endocrinol 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC4507333/
- 3
Filicori M, et al. Pulsatile GnRH (gonadorelin) therapy for hypothalamic amenorrhoea and GnRH stimulation testing — clinical review J Clin Endocrinol Metab 1994.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.
